UK markets closed

ZYME Oct 2024 20.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
1.00000.0000 (0.00%)
At close: 10:30AM EDT
Full screen
Previous close1.0000
Open1.0000
Bid0.0500
Ask2.5500
Strike20.00
Expiry date2024-10-18
Day's range1.0000 - 1.0000
Contract rangeN/A
Volume2
Open interest4
  • GlobeNewswire

    Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer

    VANCOUVER, British Columbia, July 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Leone Patterson as Executive Vice President, and Chief Business and Financial Officer, effective September 1, 2024. “After an extensive search, we are delighted to have Leone Patterson join us at

  • GlobeNewswire

    Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate

    VANCOUVER, British Columbia, July 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for ZW191, the Company’s novel folate receptor-⍺ (FR⍺) targeted topoisomerase I inhibitor (TOPO1i

  • GlobeNewswire

    Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024

    VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its second quarter 2024 financial results after market close on August 1, 2024. Following the announcement, management will host a conference call and webcast to discuss financial result